CHD7 Expression Predicts Survival Outcomes in Patients with Resected Pancreatic Cancer

Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease with poor outcomes with current therapies. Gemcitabine is the primary adjuvant drug used clinically, but its effectiveness is limited. In this study, our objective was to utilize a rationale-driven approach to identify novel biomarkers...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Colbert, Lauren E., Petrova, Aleksandra V., Fisher, Sarah B., Pantazides, Brooke G., Madden, Matthew Z., Hardy, Claire W., Warren, Matthew D., Pan, Yunfeng, Nagaraju, Ganji P., Liu, Elaine A., Saka, Burcu, Hall, William A., Shelton, Joseph W., Gandhi, Khanjan, Pauly, Rini, Kowalski, Jeanne, Kooby, David A., El-Rayes, Bassel F., Staley, Charles A., Adsay, N. Volkan, Curran, Walter J., Landry, Jerome C., Maithel, Shishir K., Yu, David S.
Formato: Artigo
Idioma:Inglês
Publicado: 2014
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4025946/
https://ncbi.nlm.nih.gov/pubmed/24626090
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-13-1996
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares